Early Immunogenicity and Safety of the Third Dose of BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine Among Adults Older Than 60 Years: Real-World Experience

Posted on by

Journal of Infectious Diseases
Volume 225, Issue 5, 1 March 2022
https://academic.oup.com/jid/issue/225/5

 

Early Immunogenicity and Safety of the Third Dose of BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine Among Adults Older Than 60 Years: Real-World Experience
Mayan Gilboa, Michal Mandelboim, Victoria Indenbaum, Yaniv Lustig, Carmit Cohen …
The Journal of Infectious Diseases, Volume 225, Issue 5, 1 March 2022, Pages 785–792, https://doi.org/10.1093/infdis/jiab584
A rapid and broad immune response to the third BNT162b2 dose in 208 individuals aged >60 years is reported (33-fold and 51-fold increase in IgG and neutralizing antibody, respectively). Levels post–third dose were significantly higher than post–second dose.